[5] Contemporaneous with the spinoff in June 2013 S&P Dow Jones Indices announced that Zoetis would replace First Horizon National Corporation in the S&P 500 stock market index.

[10] In 1952, the Pfizer Agriculture Division opened a 732-acre research and development facility in Terre Haute, Indiana, called Vigo.

[15] The sell-off of Zoetis was consistent with Pfizer's recent decision to shed other non-pharmaceutical subsidiaries in an effort to save costs, raise capital, and pay off debt.

The company announced that JPMorgan Chase, Bank of America, Merrill Lynch, Goldman Sachs & Co., and Morgan Stanley would be the lead underwriters.

[22][3] Stock investors were attracted to the steep profit margin in proportion to revenue and consumer confidence in potential future growth of the subsidiary.

[29] In September 2023, Zoetis acquired Petmedix, a privately held Cambridge, UK-based company, to bring the benefits of species-specific antibody therapies to pet owners.

[30][31] Twenty-eight sites in 11 countries make up Zoetis' manufacturing network, each facility designed to meet chemical and infectious agent safety regulatory requirements.

[38] The grants have been allocated towards causes including advancing opportunities for veterinary professionals[39][40][41] and farmers,[42] providing support to those affected by the Russian invasion of Ukraine, matching gifts programs, and delivering relief to those impacted by the earthquake in the Republic of Türkiye.